
    study discontinued based on planned interim analysis of the primary endpoint. not linked to any
    safety concern.
  
['relapsing-remitting multiple sclerosis']
['vatelizumab', 'placebo (for vatelizumab)']

        Inclusion criteria:

        Diagnosis of relapsing-remitting multiple sclerosis (RRMS). At least 1 documented relapse
        in the past 12 months. At least 1 contrast-enhancing lesion (CEL) on magnetic resonance
        imaging (MRI) in the past 12 months and/or at screening.

        At least 3 T2 lesions on screening MRI.

        Exclusion criteria:

        Diagnosis of primary progressive or secondary progressive MS. Expanded disability status
        scale (EDSS) score >5.5. Relapse within 30 days prior to enrollment. Prior
        immunosuppressive treatment within protocol-specified time periods. Prior treatment with
        natalizumab (Tysabri®). History of bleeding/platelet disorders, malignancy, certain
        infections as defined in the protocol, or any other past or current medical conditions that
        would adversely affect the patient's participation in the study.

        Pregnancy or breast-feeding. Other protocol-defined inclusion/exclusion criteria may apply.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      